Psoriasis and metabolic syndrome: a review

Psoriasis is the most common chronic dermatosis and affects 1–2% of the population of developed countries. In Russia, psoriasis incidence rate has increased by 11% since 2011. Psoriasis is a chronic inflammatory and immune-mediated skin disease and it is often associated with metabolic syndrome and its components such as obesity, arterial hypertension, insulin resistance and dyslipidemia. The risk of developing metabolic syndrome in patients with psoriasis is 40% higher than in the general population. Psoriasis and metabolic syndrome share some pathogenic mechanisms such as chronic low-grade systemic inflammation and an increased level of pro-inflammatory cytokines. Systemic inflammation causes obesity, cardiovascular diseases, diabetes. These conditions increase the risk of mortality among patients. There is a link between the severity of psoriasis and metabolic syndrome and associated with severe rash, reduction of the remission and higher risk of psoriatic arthritis development. The carriers of the risk allele of FTO gene are associated with severe psoriasis, presence of psoriatic arthritis and obesity. The article presents the issues of epidemiology, etiology and pathogenesis of psoriasis and metabolic syndrome.

1. Kubanov AA, Bogdanova EV. Dermatovenereologic health care delivery management in the Russian Federation. Results of 2018. Vestnik dermatologii i venerologii. 2019;95(4):8-13. (In Russ.). doi: https://doi.org/10.25208/0042-4609-2019-95-4-8-23

2. Gisondi P, Fostini AC, Fossà I, et al. Psoriasis and the Metabolic Syndrome. Clin Dermatol. 2018;36(1):21-28. doi: https://doi.org/10.1016/j.clindermatol.2017.09.005

3. IDF.org [Internet]. The IDF worldwide definition of the metabolic syndrome [cited: 2020, Jun 02]. Available from: https://www.idf.org/e-library/consensus-statements/60-idfconsensus-worldwidedefinitionof-the-metabolic-syndrome.html

4. Expert Panel on Detection, Evaluation and T of HBC in A. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA J Am Med Assoc. 2001;285(19):2486-2497. doi: https://doi.org/10.1001/jama.285.19.2486

5. Rodríguez-Zúñiga MJM, García-Perdomo HA. Systematic Review and Meta-Analysis of the Association Between Psoriasis and Metabolic Syndrome. J Am Acad Dermatol. 2017;77(4):657-666. doi: https://doi.org/10.1016/j.jaad.2017.04.1133

6. Leskova IV, Ershova EV, Nikitina EA, et al. Obesity in Russia: modern view in the light of a social problems. Obesity and metabolism. 2019;16(1):20-26. (In Russ.). doi: https://doi.org/10.14341/omet9988

7. Kochetova OV, Akhmadishina LZ, Korytina GF, et al. Association of obesity susceptibility gene variants with metabolic syndrome in women. Obesity and metabolism. 2017;14(2):33-40. (In Russ.). doi: https://doi.org/10.14341/OMET2017233-40

8. Furue M, Tsuji G, Chiba T, et al. Cardiovascular and Metabolic Diseases Comorbid with Psoriasis: Beyond the Skin. Intern Med. 2017;56(13):1613-1619. doi: https://doi.org/10.2169/internalmedicine.56.8209.

9. Puig L, Kirby B, Mallbris L, et al. Psoriasis Beyond the Skin: A Review of the Literature on Cardiometabolic and Psychological Co-Morbidities of Psoriasis. Eur J Dermatol. 2014;24(3):305-311. doi: https://doi.org/10.1684/ejd.2014.2299

10. Takahashi H, Iizuka H. Psoriasis and Metabolic Syndrome. J Dermatol. 2012;39(3):212-218. doi: https://doi.org/10.1111/j.1346-8138.2011.01408.x

11. Singh S, Young P, Armstrong AW. An Update on Psoriasis and Metabolic Syndrome: A Meta-Analysis of Observational Studies. PLoS One. 2017;12(7):1-13. doi: https://doi.org/10.1371/journal.pone.0181039

12. Lykova SG, Morzhanaeva MA, Nemchaninova OB, et al. Psoriasis in patients with metabolic syndrome: clinical aspects of the problem. Clinical Dermatology and Venereology. 2020;19(2):214-222. (In Russ.). doi: https://doi.org/10.17116/klinderma202019021214

13. Armstrong AW, Schupp C, Bebo B. Psoriasis Comorbidities: Results from the National Psoriasis Foundation Surveys 2003 to 2011. Dermatology. 2012;225:121–126. doi: https://doi.org/10.1159/000342180

14. Khismatullina ZR, Amineva AM, Kurochkin DP, et al. Psoriasis, psoriatic arthritis, metabolic disorders and cardiovas- cular disease. What is common? Clinical Dermatology and Venereology. 2020;19(2):139-147. (In Russ.). doi: https://doi.org/10.17116/klinderma202019021139

15. Dontsova EV. Psychoemotional features of psoriasis patients with metabolic syndrome. Terra Medica. 2013;72(2):39-41. (In Russ.).

16. Dontsova EV, Nikolaeva LA. Comparative indicators` characteristic of oxidative stress in patients with psoriasis of varying severity and metabolic syndrome. Kremlevskaya medicina. Klinicheskii vestnik. 2018;1:45-48. (In Russ.).

17. Takahashi H, Iinuma S, Honma M, et al. Increased Serum C-reactive Protein Level in Japanese Patients of Psoriasis with Cardio- And Cerebrovascular Disease. J Dermatol. 2014;41(11):981-985. doi: https://doi.org/10.1111/1346-8138.12632

18. Vadakayil AR, Dandekeri S, Kambil SM, et al. Role of C-reactive Protein as a Marker of Disease Severity and Cardiovascular Risk in Patients with Psoriasis. Indian Dermatol Online J. 2015;6(5):322-325. doi: https://doi.org/10.4103/2229-5178.164483

19. Borska L, Kremlacek J, Andrys C, et al. Systemic Inflammation, Oxidative Damage to Nucleic Acids, and Metabolic Syndrome in the Pathogenesis of Psoriasis. Int J Mol Sci. 2017;18(11):2238. doi: https://doi.org/10.3390/ijms18112238

20. Pavlova TG, Matusevich SL, Shibanova NY. Antropometric parametres influence on psoriasis clinical traits. Medical science and education of Ural. 2013;73(1):46-48. (In Russ.).

21. Lykova SG, Nemchaninova OB, Pavlova TG, et al. Special considerations of methodical approach in the development of therapeutic and preventive measures to optimize the diet and some aspects of the lifestyle of patients with psoriasis. Clinical Dermatology and Venereology 2018;17(2):108-113. (In Russ.). doi: https://doi.org/10.17116/klinderma2018172108-113.

22. Nemchaninova OB, Pavlova TG, Pozdnjakova ON, et al. The influence of individual lifestyle components on the severity of clinical course in patients with psoriasis in Kemerovo region. Medical almanac. 2018;52(1):130-132. (In Russ.).

23. Perlamutrov YuN, Mikryukov AV. Clinical and laboratory characteristics of psoriasis associated with hormonal metabolic disorders. Russian Journal of Skin and Venereal Diseases. 2013;5:46-50. (In Russ.).

24. Guénard F, Houde A, Bouchard L, et al. Association of LIPA Gene Polymorphisms with Obesity-Related Metabolic Complications Among Severely Obese Patients. Obesity (Silver Spring). 2012;20(10):2075-2082. doi: https://doi.org/10.1038/oby.2012.52

25. Fall T, Ingelsson E. Genome-wide association studies of obesity and metabolic syn- drome. Mol Cell Endocrinol. 2014;382(1):740-57. doi: https://doi.org/10.1016/j.mce.2012.08.018

26. Frayling TM, Timpson NJ, Weedon MN, et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science. 2007;316(5826):889-894. doi: https://doi.org/10.1126/science.1141634

27. Gulati P, Yeo GS. The biology of FTO: from nucleic acid demethylase to amino acid sensor. Diabetologia. 2013;56(10):2113-2121. doi: https://doi.org/10.1007/s00125-013-2999-5

28. Cheung MKM, Yeo GSH. FTO biology and obesity: why do a billion of us weight 3 kg more? Front Endocrinol. 2011;2(4):1-9. doi: https://doi.org/10.3389/fendo.2011.00004

29. Wahlen K, Sjolin E, Hoffstedt J. The common rs9939609 gene variant of the fat mass and obesity-associated gene FTO is related to fat cell lipolysis J. Lipid Res. 2008;49(3):607–611. doi: https://doi.org/10.1194/jlr.M700448-JLR200

30. Mehrdad M, Doaei S, Gholamalizadeh M, et al. Association of FTO rs9939609 polymorphism with serum leptin, insulin, adiponectin, and lipid profile in overweight adults. Adipocyte. 2020;9(1):51–56. doi: https://doi.org/10.1080/21623945.2020.1722550

31. Claussnitzer M, Simon N, Dankel SN, et al. FTO obesity variant circuitry and adipocyte browning in humans. N Engl J Med. 2015;373:895-907. doi: https://doi.org/10.1056/NEJMoa1502214

32. Legry V, Cottel D, Ferrières J, et al. Effect of an FTO polymorphism on fat mass, obesity, and type 2 diabetes mellitus in the French MONICA Study. Metabolism. 2009;58(7):971-975. doi: https://doi.org/10.1016/j.metabol.2009.02.019

33. Peng S, Zhu Y, Xu F, et al. FTO gene polymorphisms and obesity risk: a meta-analysis. BMC Medicine. 2011;9(71):1-15. doi: https://doi.org/10.1186/1741-7015-9-71

34. Liguori R, Labruna G, Alfieri A, et al. The FTO gene polymorphism (rs9939609) is associated with metabolic syndrome in morbidly obese subjects from southern Italy. Molecular and Cellular Probes. 2014;28(4):195-199. doi: https://doi.org/10.1016/j.mcp.2014.03.004

35. Meyre D, Delplanque J, Chèvre JC, et al. Genome-wide association study for early- onset and morbid adult obesity identifies three new risk loci in European populations. Nat Genet. 2009;41(2).157-159. doi: https://doi.org/10.1038/ng.301

36. Sandholt CH, Sparsø T, Grarup N, et al. Combined analyses of 20 common obesity susceptibility variants. Diabetes. 2010;59(7):1667-1673. doi: https://doi.org/10.2337/db09-1042

37. Li X, Song F, Jiang H, et al. A genetic variation in the fat mass- and obesity-associated gene is associated with obesity and newly diagnosed type 2 diabetes in a Chinese population. Diabetes Metab Res Rev. 2010;26(2):128-132. doi: https://doi.org/10.1002/dmrr.1066

38. Kochetova OV, Akhmadishina LZ, Korytina GF, et al. Association of obesity susceptibility gene variants with metabolic syndrome in women. Obesity and metabolism. 2017;14(2):33-40. (In Russ.) doi: https://doi.org/10.14341/OMET2017233-40

39. Haller S, Spiegler J, Hemmelmann C, et al. Polymorphisms in FTO and MAF Genes and Birth Weight, BMI, Ponderal Index, Weight Gain in a Large Cohort of Infants with a Birth Weight below 1500 Grams. PLoS One. 2013;8(6):e66331. doi: https://doi.org/10.1371/journal.pone.0066331

40. Speakman JR, Rance KA, Johnstone AM. Polymorphisms of the FTO Gene Are Associated with Variation in Energy Intake, but Not Energy Expenditure. Obesity (Silver Spring). 2008;16(8):1961-1965. doi: https://doi.org/10.1038/oby.2008.318

41. Castellini G, Franzago M, Bagnoli S, et al. Fat mass and obesityassociated gene (FTO) is associated to eating disorders susceptibility and moderates the expression of psychopathological traits. PLoS ONE. 2017;12(3):1-14. doi: https://doi.org/10.1371/journal.pone.0173560

42. Karra E, O’Daly OG, Choudhury AI, et al. A Link Between FTO, Ghrelin, and Impaired Brain Food-Cue Responsivity. J Clin Invest. 2013;123(8):3539-3551. doi: https://doi.org/10.1172/JCI44403

43. Danga LC, Samanez-Larkin GR, Smith CT, et al. FTO affects food cravings and interacts with age to influence age-related decline in food cravings. Physiology & Behavior. 2018;192(1):188-193. doi: https://doi.org/10.1016/j.physbeh.2017.12.013

44. Bondareva EA, Zadorozhnaya LV, Khomyakova IA. T/A polymorphism of the FTO gene and lifestyle are associated with fat accumulation in different age groups of men. Obesity and metabolism. 2019;16(2):49-53. (In Russ.). doi: https://doi.org/10.14341/omet9798

45. Zhang Q, Xia X, Fang S, Yuan X. Relationship Between Fat Mass and Obesity-Associated (FTO) Gene Polymorphisms with Obesity and Metabolic Syndrome in Ethnic Mongolians. Samuels DC, ed. Med Sci Monit. 2018;24(6):8232-8238. doi: https://doi.org/10.12659/MSM.910928

46. Rutters F, Nieuwenhuizen AG, Bouwman F, et al. Associations between a single nucleotide polymorph- ism of the FTO Gene (rs9939609) and obesity-related characteristics over time during puberty in a Dutch children cohort. J Clin Endocrinol Metab. 2011;96(6):939–942. doi: https://doi.org/10.1210/jc.2010-2413

47. Labayen I, Ruiz JR, Ortega FB, et al. Association between the FTO rs9939609 polymorphism and leptin in European adolescents: a possible link with energy balance control. The HELENA Study. Int J Obesity. 2011;35(1):66. doi: https://doi.org/10.1038/ijo.2010.219

48. Duicu C, Mărginean CO, Voidăzan S, et al. FTO rs 9939609 SNP Is Associated With Adiponectin and Leptin Levels and the Risk of Obesity in a Cohort of Romanian Children Population. Medicine (Baltimore). 2016;95(20):e3709. doi: https://doi.org/10.1097/MD.0000000000003709

49. Xi B, Shen Y, Zhang M, et al. The common rs9939609 variant of the fat mass and obesity-associated gene is associated with obesity risk in children and adolescents of Beijing, China. BMC Med Genet. 2010;11(1):107. doi: https://doi.org/10.1186/1471-2350-11-107

50. He D, Fu M, Miao S, et al. FTO gene variant and risk of hypertension: A meta-analysis of 57,464 hypertensive cases and 41,256 controls. Metabolism. 2014;63(5):633-639. doi: https://doi.org/10.1016/j.metabol.2014.02.008

51. Coto-Segura P, González-Lara L, Eiris N, et al. Effect of the FTO rs9930506 polymorphism on obesity and the main clinical outcomes in patients with psoriasis. British Journal of Dermatology. 2014;171(4):917-919. doi: https://doi.org/10.1111/bjd.13000

52. Tupikowska-Marzec M, Kolačkov K, Zdrojowy-Wełna A, et al. The Influence of FTO Polymorphism rs9939609 on Obesity, Some Clinical Features, and Disturbance of Carbohydrate Metabolism in Patients with Psoriasis. Biomed Res Int. 2019;2019:1-5. doi: https://doi.org/10.1155/2019/7304345